Novavax's shares slid 19% after topline data from a new phase 2 trial on its RSV vaccine fail to impress investors.
BiodVax will test its universal flu vaccine candidate M-001 as a standalone shot after it elicited positive immune responses as a primer in a phase 2b trial.
With early HIV vaccine results announced Monday, Johnson & Johnson and its partners hope they might have a winner.
VBI Vaccines hopes to challenge the hepatitis B vaccine standard-of-care, a position long held by GlaxoSmithKline’s Engerix-B.
Using a painless microneedle patch, scientists are trying to take the "Ow!" out of flu shots.
While GSK is still expected to top the vaccine industry in 2022, rankings for other players have shifted in Evaluate's new World Preview.
Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.